December 2016 - January 2017 Newsletter
IASLC Now Accepting Applications for 2017-2018 Lung Cancer Fellowship and Young Investigator Awards
The International Association for the Study of Lung Cancer (IASLC) is proud to announce the annual IASLC Fellowship and Young Investigators Programs.
Applications are requested for the 2017 - 2018 Fellowship and Young Investigator award cycle. There will be a minimum of three awards of $50,000, each for the duration of one year, with at least one recipient from each region (North America, Europe, and the rest of the world) funded. The funding period will be July 1, 2017 – June 30, 2018.
The goal is to reward scientific excellence and to encourage innovative research in lung cancer prevention and translational medicine. Applications will be evaluated by a Scientific Review Panel for their merit, innovation, and potential impact on the management of lung cancer.
Applications Now Being Accepted for the 2017 ALCF-IASLC Joint Fellowship Award for the Early Detection of Lung Cancer
The Bonnie J. Addario Lung Cancer Foundation (ALCF), in collaboration with the International Association for the Study or Lung Cancer (IASLC), is pleased to announce their second joint Fellowship Award to support novel, innovative, and translational research with potential of high clinical impact on the early detection of lung cancer.
The joint, international ALCF-IASLC Fellowship award was first instituted in 2015 by the two organizations to support an early career scientist’s training and research on early detection modalities in an established lung cancer research laboratory of their choice, anywhere in the world. ALCF and IASLC have jointly funded an early career scientist in 2016, and are now pleased to announce the request for applications for the second joint award. The deadline to submit applications is March 1, 2017.
IASLC's 17th WCLC a Great Success in Vienna, Austria
The IASLC 17th World Conference on Lung Cancer (IASLC 17th WCLC) took place this year in Vienna, Austria, from December 4-7, 2016. Under the leadership of Dr. Robert Pirker and his organizing committee, the conference was a great success, drawing nearly 6,500 attendees from approximately 100 countries. Over the course of four days, nearly 2,000 scientific presentations were given on a wide-range of topics.
Conference attendees may be eligible to claim CME credit. The IASLC designates this live activity for a maximum of 27 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Those who were unable to attend the conference in person can also access the virtual meeting through the IASLC website. The cost of access is $99.00 USD for IASLC members.
Finally, please save the date for the IASLC 18th World Conference on Lung Cancer (WCLC2017). This year's conference will take place October 15-18, 2017, in Yokohama, Japan. Visit the conference's official website for information on the abstract submission process, registration, and more!
Successful Conclusion to the IASLC Fellowship Matching Challenge
Over the past few months, the IASLC Foundation has been running the Fellowship Matching Challenge. From the beginning of October through December 31, 2016, the IASLC Board and the IASLC Foundation Board matched dollar-for-dollar any new or increased donations to the IASLC Foundation.
Thank you to all who made a donation during this challenge period! Leveraged by the challenge, the IASLC Foundation raised over $64,000 during 2016.
All donations to the IASLC Foundation go towards funding new fellowships for promising, young lung cancer researchers. Even though the Challenge is now over, you can still make a donation to the IASLC Foundation. Contributions of any size will help us continue the exciting progress we've made over the past few months and allow for more fellowships to be funded.
IASLC 2016 Member Opinion Survey
The IASLC seeks to receive feedback on Membership benefits, programs, and services. The survey can be completed within 5 minutes and we appreciate as much detailed feedback as you wish to share. Responses are due by February 15, 2017. All survey respondents will be entered into a random drawing to win an Apple iPad!
By now, you should have received the survey in your inbox; please contact us if you have not already received the invitation. Please also note that submissions are anonymous and answers will be desegregated from contact details, unless you choose to provide contact details at the end. We thank you for your support of IASLC and your work to conquer lung cancer. Feel free to contact firstname.lastname@example.org if you have any questions.
World Cancer Day is February 4, 2017
World Cancer Day (WCD) is February 4, 2017. WCD's goal is to unite the world's population in the fight against cancer.
The campaign "aims to save millions of preventable deaths each year by raising awareness and education about the disease." For more information, visit the campaign's official website or follow it on Facebook, Twitter, or Instagram.
Academic, Career, Funding Opportunities
As a service to our members, we post opportunities related to lung cancer and other thoracic malignancies on our website.
This now includes academic career opportunities. Click here to review post-doctoral and other career opportunities submitted to IASLC. If you have an academic career opportunity, please email it to email@example.com.
We also post opportunities when we receive information from grantors. We currently have two funding opportunities:
These opportunities are available to applicants from all countries. Click here to learn more.
Social Media Corner: Wrapping Up #WCLC2016
Social media played a large role at this year's IASLC 17th World Conference on Lung Cancer (WCLC2016), which took place December 4-7, 2016 in Vienna, Austria. Through the combined efforts of IASLC staff members and the active participation of a variety of conference attendees, the official hashtag for the conference, #WCLC2016, trended each day of the conference.
This is a remarkable accomplishment, critical to our goals of raising awareness for the IASLC and lung cancer itself, and indicative of the commitment and passion of those who attended the conference and shared their observations. See more information on how the #WCLC2016 hashtag was utilized at this year's conference and who the top participants were.
For those planning to attend the IASLC 18th World Conference on Lung Cancer, please note that the hashtag will be #WCLC2017. We hope everyone will join us in making the biggest possible impact. Visit the conference's official website for more information.
December 2016 and January 2017: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The selected articles will be made available to the public for a limited time upon printing. The articles below from the December 2016 and January 2017 issues of the JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
The introduction of immune check point inhibitors into the clinic for lung cancer therapy has brought to the forefront a number of unique immune-related toxicities. Most of these are related to activated T-cells attacking normal “self” organs – a mechanism akin to the syndrome of previously recognized autoimmune diseases. Thus, these toxicities are managed in a similar manner to that of autoimmune diseases. However, up till now, the bulk of clinical experience has been limited to the western societies of Europe and North America. As the use of these agents spread globally with a wide array of infectious pathogens and environmental insults, novel toxicities may be unearthed.
The IASLC mesothelioma staging committee has come up with four articles. Pass and colleagues provide the background and rationale for the staging project in “The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation”. This is followed by a series of three articles by Nowak et al, Rice et al and Rusch et al on proposals for the revision of the T, N and M descriptors respectively.
This is the start of a new year and we have broken tradition in the selection of our featured articles. The emergence of MET as a valid target in lung cancer is an unusual story – that of major failures in two large phase III studies, leading to the conventional wisdom that MET was not a valid target in NSCLC, followed years later by the identification of MET skipping mutations and the re-emergence of MET as a potential target for NSCLC therapy. Thus, we have selected four articles dealing with MET.
The following articles were selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with press releases that were released at the time of online publication (Published Ahead of Print).
To read more IASLC Press Releases, please visit IASLC Research Articles. These press releases are also announced via social media, so please follow IASLC on Twitter, LinkedIn, and Facebook to stay up to date on the latest scientific topics. Also please follow the JTO on Twitter and Facebook.
Histologic Classification Impacts the Efficacy of SBRT Treatment in Early-Stage Lung Cancer Patients
Early-stage non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma (SqCC) have a significantly higher rate of local failure after stereotactic body radiation therapy (SBRT) than other NSCLC histological subtypes.
All members whose memberships expired December 31, 2016, will receive renewal notices. If you chose a multi-year membership in 2016, your membership will continue uninterrupted.
IASLC has continued the three-year registration options for all categories (except complimentary Fellow Membership). Our three-year option "locks-in" the current membership rates. Regular members will save $150.00 over three years by selecting the Three-Year Membership option ($600.00). Developing Country Members and Allied Health Professionals can avoid potential future increases and not have to renew each year.
We encourage all members to renew early to ensure there is no interruption of benefits such as JTO delivery and online access. Please review the single-year and multi-year options available to you!
Thinking about joining IASLC as a New Member? Watch the video below to understand why IASLC is an organization like no other!
Updating Member Contact Details and Member Directory Preferences
It’s important for the IASLC to keep our records up to date so that members can receive important information via email and post. To ensure that our records are current, the IASLC will be contacting individuals from whom we have received bounced emails or postal mail back to our headquarters.
Additionally, all members will be sent a communication to verify personal details that will be included in the Member Directory. The communication also asks your preferences for delivery of the IASLC Member Directory, which can be mailed to members at no charge. You can also opt-out of print delivery and simply access the online directory at any time.
To make updates to your IASLC account, simply sign into your account. You may also send updates to firstname.lastname@example.org or call 720-325-2956.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.